Adagene (ADAG) News Today $2.09 -0.13 (-5.86%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Adagene Inc. (NASDAQ:ADAG) Sees Large Decrease in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 12,300 shares, a decline of 42.5% from the October 15th total of 21,400 shares. Based on an average daily trading volume, of 88,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are short sold.November 13, 2024 | marketbeat.comAdagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNovember 7, 2024 | globenewswire.comCoya stock tumbles 23% on mixed results from Alzheimer's studyOctober 29, 2024 | msn.comAdagene Inc. (NASDAQ:ADAG) Short Interest Down 30.7% in OctoberAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 21,400 shares, a decrease of 30.7% from the September 30th total of 30,900 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 75,400 shares, the short-interest ratio is presently 0.3 days.October 27, 2024 | marketbeat.comAdagene And 2 Other US Penny Stocks To ConsiderOctober 22, 2024 | finance.yahoo.comAdagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 9, 2024 | globenewswire.comAdagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG)Adagene Inc. (NASDAQ:ADAG - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Adagene in a note issued to investors on Wednesday, September 18th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.78) fSeptember 20, 2024 | marketbeat.comBuy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market UnderappreciationSeptember 19, 2024 | markets.businessinsider.comAdagene (NASDAQ:ADAG) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of Adagene in a research note on Wednesday.September 18, 2024 | marketbeat.comAdagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)September 16, 2024 | globenewswire.comCD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027September 12, 2024 | finance.yahoo.comAdagene to Participate in Investor Conferences in SeptemberAugust 29, 2024 | finance.yahoo.comAdagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in AugustAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 13,000 shares, a growth of 170.8% from the July 31st total of 4,800 shares. Currently, 0.0% of the company's stock are sold short. Based on an average trading volume of 49,500 shares, the short-interest ratio is presently 0.3 days.August 28, 2024 | marketbeat.comAdagene Inc. (NASDAQ:ADAG) Short Interest UpdateAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,800 shares, a decrease of 34.2% from the July 15th total of 7,300 shares. Based on an average daily trading volume, of 30,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company's stock are short sold.August 14, 2024 | marketbeat.comMorgan Stanley Reaffirms Their Buy Rating on Adagene (ADAG)August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Poseida Therapeutics Amidst Promising Clinical and Financial UpdatesAugust 6, 2024 | markets.businessinsider.comBuy Rating on Adagene: Market Advantage and Promising Clinical Trials Fuel Growth PotentialJuly 23, 2024 | markets.businessinsider.comAdagene Inc ADR ADAGJuly 19, 2024 | morningstar.comAdagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in JuneAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 19,700 shares, a growth of 45.9% from the June 15th total of 13,500 shares. Based on an average trading volume of 31,900 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company's stock are short sold.July 13, 2024 | marketbeat.comAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in SeptemberJuly 12, 2024 | globenewswire.comAdagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 13,500 shares, a growth of 400.0% from the May 31st total of 2,700 shares. Based on an average daily volume of 32,700 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the company's stock are short sold.June 27, 2024 | marketbeat.comAdagene Inc. (NASDAQ:ADAG) Short Interest Down 75.7% in MayAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,700 shares, a decline of 75.7% from the May 15th total of 11,100 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 32,000 shares, the days-to-cover ratio is presently 0.1 days.June 12, 2024 | marketbeat.comAdagene Inc. (NASDAQ:ADAG) Sees Significant Decrease in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 11,100 shares, a drop of 26.5% from the April 30th total of 15,100 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 34,900 shares, the short-interest ratio is presently 0.3 days.May 30, 2024 | marketbeat.comAdagene to Present at Investor Conferences in JuneMay 22, 2024 | globenewswire.comWuXi AppTec Co. Ltd. Takes Position in Adagene Inc. (NASDAQ:ADAG)WuXi AppTec Co. Ltd. acquired a new stake in Adagene Inc. (NASDAQ:ADAG - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,225,696 shares of the company's stock, vMay 8, 2024 | marketbeat.comMorgan Stanley lifts Adagene stock target on positive dataApril 10, 2024 | investing.comAdagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 31, 2024 | finanznachrichten.deAdagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | globenewswire.comAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardMarch 7, 2024 | globenewswire.comAdagene to Present at the Leerink Partners Global Biopharma Conference 2024February 27, 2024 | globenewswire.comAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)February 9, 2024 | finance.yahoo.comWeek In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure TherapyJanuary 21, 2024 | seekingalpha.comMesoblast rises after cell therapy gets FDA rare pediatric disease designationJanuary 19, 2024 | msn.comHow Is The Market Feeling About Adagene?January 18, 2024 | benzinga.comMorgan Stanley 'encouraged' by 2 cPRs reported by AdageneJanuary 17, 2024 | realmoney.thestreet.comWhy Is Cancer Focused Adagene Stock Plummeting Today?January 17, 2024 | benzinga.comAdagene falls after trial data for cancer therapyJanuary 17, 2024 | msn.comAdagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 16, 2024 | finance.yahoo.comAdagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewardedJanuary 10, 2024 | finance.yahoo.comAdagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumJanuary 4, 2024 | finance.yahoo.comNKGen doses first patient in Phase 1/2a Alzheimer's studyDecember 28, 2023 | msn.comAdagene price target lowered by 40c at Morgan Stanley, here's whyDecember 20, 2023 | realmoney.thestreet.comDeka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of DirectorsDecember 19, 2023 | markets.businessinsider.comAdagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023November 3, 2023 | finance.yahoo.comAre Medical Stocks Lagging Medpace (MEDP) This Year?October 13, 2023 | finance.yahoo.comAdagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOctober 12, 2023 | finance.yahoo.comAdagene Inc - ADR (ADAG) Price Target Increased by 9.87% to 14.04October 5, 2023 | msn.comAdagene’s Strong Potential: A Buy Rating Backed by Evorpacept Trials and Promising CD47-Targeted TherapiesOctober 4, 2023 | markets.businessinsider.comPotential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without RiskSeptember 9, 2023 | finance.yahoo.comAdagene to Present at Investor and Scientific Conferences in SeptemberSeptember 7, 2023 | finance.yahoo.com Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here ADAG Media Mentions By Week ADAG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAG News Sentiment▼1.430.46▲Average Medical News Sentiment ADAG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAG Articles This Week▼00▲ADAG Articles Average Week Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QNCX News Today IPHA News Today CGEN News Today CUE News Today XLO News Today MEIP News Today AMLX News Today DNA News Today ALEC News Today QTTB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
